An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
- PMID: 11017145
- DOI: 10.1038/80474
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Erratum in
- Nat Med 2000 Dec;6(12):1412
Abstract
Replication-selective oncolytic viruses constitute a rapidly evolving and new treatment platform for cancer. Gene-deleted viruses have been engineered for tumor selectivity, but these gene deletions also reduce the anti-cancer potency of the viruses. We have identified an E1A mutant adenovirus, dl922-947, that replicates in and lyses a broad range of cancer cells with abnormalities in cell-cycle checkpoints. This mutant demonstrated reduced S-phase induction and replication in non-proliferating normal cells, and superior in vivo potency relative to other gene-deleted adenoviruses. In some cancers, its potency was superior to even wild-type adenovirus. Intravenous administration reduced the incidence of metastases in a breast tumor xenograft model. dl922-947 holds promise as a potent, replication-selective virus for the local and systemic treatment of cancer.
Similar articles
-
An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.Cancer Res. 2003 Apr 1;63(7):1490-9. Cancer Res. 2003. PMID: 12670895
-
A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.J Gene Med. 2006 Oct;8(10):1232-42. doi: 10.1002/jgm.953. J Gene Med. 2006. PMID: 16900558
-
A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.Cancer Res. 2001 Sep 1;61(17):6428-36. Cancer Res. 2001. PMID: 11522637
-
Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.Clin Cancer Res. 2006 Nov 1;12(21):6523-31. doi: 10.1158/1078-0432.CCR-06-1491. Clin Cancer Res. 2006. PMID: 17085667
-
Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.Cancer Gene Ther. 2004 Aug;11(8):555-69. doi: 10.1038/sj.cgt.7700735. Cancer Gene Ther. 2004. PMID: 15232601
Cited by
-
Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells.PLoS Pathog. 2015 Feb 12;11(2):e1004657. doi: 10.1371/journal.ppat.1004657. eCollection 2015 Feb. PLoS Pathog. 2015. PMID: 25674795 Free PMC article.
-
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186794 Free PMC article.
-
Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas.Neoplasia. 2005 Jan;7(1):48-56. doi: 10.1593/neo.04391. Neoplasia. 2005. PMID: 15720816 Free PMC article.
-
Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.Cancer Sci. 2010 Feb;101(2):482-7. doi: 10.1111/j.1349-7006.2009.01409.x. Epub 2009 Oct 20. Cancer Sci. 2010. PMID: 19922505 Free PMC article.
-
Conditionally replicating adenoviruses for cancer treatment.Curr Cancer Drug Targets. 2007 May;7(3):285-301. doi: 10.2174/156800907780618301. Curr Cancer Drug Targets. 2007. PMID: 17504125 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources